Stock Research for AMRN


Featured Broker: Ally Invest

Get the due diligence for another stock.


AMRN Stock Chart & Research Data

The AMRN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AMRN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


AMRN Due diligence Resources & Stock Charts

The AMRN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View AMRN Detailed Price Forecast - CNN Money CNN View AMRN Detailed Summary - Google Finance
Yahoo View AMRN Detailed Summary - Yahoo! Finance Zacks View AMRN Stock Research & Analysis -

Stock Analysis

TradeIdeas View AMRN Trends & Analysis - Trade-Ideas Barrons View AMRN Major Holders - Barrons
NASDAQ View AMRN Call Transcripts - NASDAQ Seeking View AMRN Breaking News & Analysis - Seeking Alpha
Spotlight View AMRN Annual Report - OTC Report View AMRN OTC Short Report -
TradeKing View AMRN Fundamentals - TradeKing Charts View AMRN SEC Filings - Bar Chart
WSJ View Historical Prices for AMRN - The WSJ Morningstar View Performance/Total Return for AMRN - Morningstar
MarketWatch View the Analyst Estimates for AMRN - MarketWatch CNBC View the Earnings History for AMRN - CNBC
StockMarketWatch View the AMRN Earnings - StockMarketWatch MacroAxis View AMRN Buy or Sell Recommendations - MacroAxis
Bullish View the AMRN Bullish Patterns - American Bulls Short Pains View AMRN Short Pain Metrics -

Social Media Mentions

StockTwits View AMRN Stock Mentions - StockTwits PennyStocks View AMRN Stock Mentions - PennyStockTweets
Twitter View AMRN Stock Mentions - Twitter Invest Hub View AMRN Investment Forum News - Investor Hub
Yahoo View AMRN Stock Mentions - Yahoo! Message Board Seeking Alpha View AMRN Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for AMRN - Insider Cow View Insider Transactions for AMRN - Insider Cow
CNBC View AMRN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for AMRN - OTC Markets
Yahoo View Insider Transactions for AMRN - Yahoo! Finance NASDAQ View Institutional Holdings for AMRN - NASDAQ

Stock Charts

FinViz View AMRN Stock Insight & Charts - StockCharts View AMRN Investment Charts -
BarChart View AMRN Stock Overview & Charts - BarChart Trading View View AMRN User Generated Charts - Trading View

Latest Financial News for AMRN

Amarin's Vascepa cuts occurrence of serious heart problems 30 pct -study
Posted on Monday March 18, 2019

A high dose of Amarin Corp's Omega-3 drug Vascepa significantly reduced the occurrence of first and subsequent heart attacks, strokes and other serious heart problems in high-risk patients already taking cholesterol medication by even more than initially reported, according to data presented on Monday. Compared with a placebo, Vascepa cut the combined rate of heart attacks, strokes, heart-related death, need for artery-clearing procedures and hospitalizations for unstable angina by 30 percent in heart disease patients at high risk for such events. Amarin in September released initial results from the study of 8,179 patients already taking other heart drugs that showed a 25 percent reduction of serious heart events for those receiving a 4 gram dose of Vascepa compared with placebo, data that sent its share price surging from around $3 to over $12.

Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT™
Posted on Monday March 18, 2019

BEDMINSTER, N.J. and DUBLIN, March 18, 2019 /PRNewswire/ -- Amarin Corporation plc (AMRN), presented new data from its landmark cardiovascular outcomes study of its prescription therapy, Vascepa® (icosapent ethyl), the REDUCE-IT™ study, showing that Vascepa provided a statistically significant 30% risk reduction in total (first and subsequent) cardiovascular events compared to placebo in the statin-treated patient population studied in REDUCE-IT.

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of DBVT, AMRN, WTW and CRBP
Posted on Sunday March 17, 2019

The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amarin Corporation plc of Class Action Lawsuit and Upcoming Deadline – AMRN
Posted on Sunday March 17, 2019

NEW YORK, NY / ACCESSWIRE / March 17, 2019 / Pomerantz LLP announces that a class action lawsuit has been filed against Amarin Corporation plc (''Amarin'' or the ''Company'') (AMRN) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and indexed under 19-cv-08423, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired the publicly traded securities of Amarin Corporation plc (''Amarin'' or the ''Company'') between September 24, 2018 and November 9, 2018 (the ''Class Period''), who were damaged thereby seeking to pursue remedies under the Securities Exchange Act of 1934 (the ''Exchange Act''). If you are a shareholder who purchased Amarin securities between September 24, 2018, and November 9, 2018, both dates inclusive, you have until April 23, 2019, to ask the Court to appoint you as Lead Plaintiff for the class.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.